Our collaborators are presenting three studies at the 2015 ASCO Genitourinary Cancers Symposium held in Orlando, Fla., that demonstrate how the Epic Sciences no cell left behind™ platform could be used as a blood test for certain types of metastatic prostate and bladder cancers — liquid biopsies to predict which patients will best respond to certain therapies before they are treated.
2015 ASCO GU POSTER PRESENTATIONS:
1. Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (Abstract 147)
Thursday 11:30 am to 1:00 pm and 5:15 pm to 6:45 pm EST (Poster Session A)
Highlight: Selected for Audio Poster Tour
2. Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC. (Abstract 197)
Thursday 11:30 am to 1:00 pm and 5:15 pm to 6:45 pm EST (Poster Session A)
3. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle-invasive (MIBC) and metastatic bladder cancer (mBCa) patients. (Abstract 353)
Friday 12:15 pm to 1:45pm and 6:00 pm to 7:00 pm (Poster Session B)